Triple receptor agonism
Simultaneous activity at three receptors from one molecule is the defining feature in comparative pharmacology.
- GIP receptor
- GLP-1 receptor
- Glucagon receptor
RP-HPLC · 214nm
99%+ HPLCPASS
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731.32 g/mol
- CAS / identifier
- 2381089-83-2
- Appearance
- White lyophilised powder
- Solubility
- Soluble in bacteriostatic water
- Storage
- -20°C long term, protect from light
- Purity
- 99%+ by RP-HPLC, 214 nm
- Identity
- Retention time matches certified reference standard
- Ships from
- United States
Lyophilised powder · 99%+ documented HPLC
Ships from USAView COA
GLP-3 RT Peptide
Triple-agonist research peptide for next-generation metabolic models.
$99.99per 10mg vial
Vial size
1
Purity 99%+RP-HPLC documented
Identity conformsreference standard match
- Ships from the US
- Discreet packaging
- Free shipping over $250
- 39
- Amino acid residues in the acylated chain.
- 3
- Receptor targets described in the class literature: GIP, GLP-1 and glucagon.
- 99%+
- Documented HPLC purity, lot by lot.
- 3rd-party
- Independently assayed.
Figures are structural data from our specification and certificates, or are drawn from published third-party literature about the compound, and are provided for orientation only. Nothing here is a claim about what this material does. Supplied for laboratory research use only.
01About this compound
What GLP-3 RT is
GLP-3 RT is a single-molecule triple agonist engaging the GIP, GLP-1 and glucagon receptors. The added glucagon-receptor arm is studied for its contribution to energy-expenditure endpoints in preclinical adiposity models. A next-generation research compound of intense current interest.
- Receptor class
- GIP + GLP-1 + glucagon
- Residues
- 39
- Typical half-life
- ~6 days (class literature)
- Form
- Lyophilised powder
- Presentation
- 10mg, 20mg and 30mg vials
Sequence
- GIP/GLP
- 1/glucagon triple agonist
BACKBONE IMPRESSION · NOT A STRUCTURAL MODEL
Atomic composition
677atoms
- 221
- 342
- 46
- 68
C221H342N46O68 · composition, not conformation
02MechanismHow GLP-3 RT
How GLP-3 RT
has been studied.
Signalling pathways examined in preclinical models. Descriptive of published research directions, not claims of effect.
Glucagon-receptor arm
The glucagon component is the element distinguishing this class from dual incretin agonists, and is studied for energy-expenditure contribution.
- Energy expenditure endpoints
- Adiposity models
Extended half-life
Class literature reports a circulating half-life around six days, a consequence of the acylated backbone.
- Long circulating half-life
- Acylated backbone
03Uses & applications
What GLP-3 RT is researched for
Metabolic research
Energy balance
Used as a comparator where triple-receptor engagement is the variable under study.
Comparative pharmacology
Class benchmarking
Referenced against dual-incretin and single-incretin agonists in receptor-selectivity work.
04Class comparison
How it compares in its class
Reference class characteristics for orientation. Half-life figures are typical literature values, not lot measurements.
| Compound | Receptor class | Typical half-life | Note |
|---|---|---|---|
| GLP-3 RT | GIP+GLP-1+GCG | ~6 days | Triple agonist |
| GLP-1 | GLP-1 | ~7 days | Single incretin |
05Selectivity
Selectivity profile
A multi-axis orientation profile. Relative, not absolute affinity data.
GLP-3 RT
- GLP-1
- 8280
- GIP
- 9586
- Glucagon
- 2074
- Half-life
- 8882
- Selectivity
- 7866
Axes are normalised 0 to 100 for comparison. These are directional summaries of published class data, not measured binding constants for this lot.
06Pharmacokinetics
Illustrative PK decay
A relative plasma-concentration model over time, normalised so the peak reads 100.
GLP-3 RT
Illustrative. A typical profile for the compound class, not a measured result for this product.
07Research history
Class research timeline
Milestones in the study of this compound class.
- 2020
Triple-agonist concept advanced in the incretin literature.
- 2022
Early-phase class data on triple-receptor endpoints reported.
- 2023
Receptor-binding and signalling characterisation published for the class.
- 2025
Established as a triple-receptor reference compound in incretin research.
08Documentation
Certificates of analysis
Every lot is documented by an independent laboratory. The newest lot appears first.
| Lot | Reported | Size | HPLC | Laboratory | Certificate |
|---|---|---|---|---|---|
| Y4AWYQ | 11 Jul 2026 | 30mg | 99% | pH Solutions | View |
| 2NPVBM | 6 Jul 2026 | 60mg | 99% | pH Solutions | View |
| PSNN1N | 6 Jul 2026 | 10mg | 99.90% | Freedom Diagnostics | View |
| Q1FC9X | 6 Jul 2026 | 30mg | 99.59% | Freedom Diagnostics | View |
| K3BQAA | 11 Jun 2026 | 10mg | 99.91% | Freedom Diagnostics | View |
| FTWSKM | 11 Jun 2026 | 30mg | 99.90% | Freedom Diagnostics | View |
| PJQK5S | 29 May 2026 | 10mg | 99.81% | Freedom Diagnostics | View |
| GR12-052026-4 | 14 May 2026 | 12mg | 99.72% | Freedom Diagnostics | View |
| GR24-052026-1 | 14 May 2026 | 24mg | 99.82% | Freedom Diagnostics | View |
| GR48-052026-1 | 14 May 2026 | 48mg | 99.47% | Freedom Diagnostics | View |
Newest lot
99%
HPLC purity
- Lot
- Y4AWYQ
- Certificate reported
- 11 Jul 2026
- Released to sale
- 13 Jul 2026
- Size
- 30mg
- Identity
- Retention time matches certified reference standard
- Content
- 30mg target fill, 337/337 vials conformant
- Appearance
- White to off-white lyophilised cake
- Laboratory
- pH Solutions
The signed PDF is the full certificate. The accession and search code above resolve the same record at the laboratory.
09Third-party verifiedIndependently tested.
Independently tested.
Verifiably pure.
- PASS
HPLC purity
RP-HPLC, 214 nm
- CONFIRMED
Identity
LC-MS
Certificate of analysis
PASSLot Y4AWYQ
RP-HPLC · 214nm11 Jul 2026
- HPLC purity
- 99%
- Identity
- Retention time matches certified reference standard
- Laboratory
- pH Solutions
- Net content
- 30mg target fill, 337/337 vials conformant
10Full specification
Every field on the label
- Sequence
- GIP/GLP-1/glucagon triple agonist
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731.32 g/mol
- CAS / identifier
- 2381089-83-2
- Quantity per vial
- 10 mg
- Purity
- 99% by RP-HPLC, 214 nm
- Identity
- Retention time matches certified reference standard
- Appearance
- White lyophilised powder
- Solubility
- Soluble in bacteriostatic water
- Storage
- -20°C long term, protect from light
- Ships from
- United States
- Lot
- Y4AWYQ
- Assay date
- 11 Jul 2026
This material is supplied as a reference standard for in-vitro laboratory research only. It has not been evaluated by the FDA, is not a drug, and is not intended for human or veterinary use. Handling should follow your institution's chemical hygiene plan, including appropriate PPE and documented disposal.
Every lot is released against a ≥99% specification by reversed-phase HPLC. Released lots have measured between 99% and 99.91%; the figure for the lot you receive is printed on its certificate rather than quoted as a range.
Yes — one per lot, signed by the testing laboratory, with the lot number, the HPLC result, identity confirmation and the measured net peptide content. Every certificate we hold is published in the COA library, including for lots no longer in stock.
10mg, 20mg and 30mg vials. Certificates exist for other fill weights because the same material is released in bulk sizes for wholesale; those lots appear in the certificate table but are not sold on this page.
A 39-residue acylated backbone with GIP, GLP-1 and glucagon receptor activity. Identity is confirmed lot-by-lot against a certified reference standard, by retention-time match on the certificates published for this compound, and that confirmation rather than a transcribed sequence is what the certificate reports.
12Cited sources
Published literature
Independent published research relating to this compound. Listed for reference; Serviam Bio Labs is not affiliated with these authors and makes no claims based on their findings.
- [1]
Triple incretin/glucagon receptor agonism
Coskun T. et al. · 2022 · Nature Metabolism
mechanism - [2]
Glucagon-receptor contribution to energy expenditure
Class literature · 2023 · Cell Reports Medicine
mechanism - [3]
Pharmacokinetics of long-acting triple agonists
Class literature · 2023 · Clinical Pharmacokinetics
pk
Research library
The evidence behind this page
For laboratory research use only. All compounds listed on this site are sold strictly as reference materials for in-vitro laboratory research conducted by qualified professionals. They are not drugs, foods, cosmetics, or medical devices. They are not intended for human or veterinary consumption, therapeutic use, diagnostic application, or any in-vivo use whatsoever. These statements have not been evaluated by the Food and Drug Administration. By purchasing, you affirm that you are a qualified researcher and that you will comply with all applicable institutional, local, state and federal regulations governing the handling of research chemicals.